HB Wealth Management LLC Has $3.65 Million Holdings in AstraZeneca PLC $AZN

HB Wealth Management LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN) by 72.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,558 shares of the company’s stock after purchasing an additional 19,908 shares during the period. HB Wealth Management LLC’s holdings in AstraZeneca were worth $3,649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AZN. NewSquare Capital LLC lifted its stake in shares of AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the period. Richardson Financial Services Inc. raised its holdings in AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of AstraZeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after acquiring an additional 275 shares during the period. VSM Wealth Advisory LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $33,000. Finally, FSA Wealth Management LLC increased its position in shares of AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after purchasing an additional 376 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $94.65 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The firm has a market cap of $293.55 billion, a PE ratio of 31.45, a price-to-earnings-growth ratio of 1.56 and a beta of 0.34. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $96.51. The company’s 50-day moving average price is $90.33 and its two-hundred day moving average price is $81.90.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $2.08 earnings per share. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Wall Street Zen raised shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Guggenheim restated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Finally, Cowen reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.